Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia

被引:0
|
作者
Chen, Jianmin [1 ,2 ,3 ]
Chen, Juan [1 ]
Feng, Baozhu [1 ]
Ning, Meilian [1 ]
Wu, Wanhui [1 ]
Zou, Shiqi [1 ]
机构
[1] Putian Univ, Sch Pharm, Putian 351100, Fujian, Peoples R China
[2] Putian Univ, Fujian Prov Univ, Key Lab Pharmaceut Anal, Putian, Fujian, Peoples R China
[3] Putian Univ, Fujian Prov Univ, Lab Med, Putian, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
allopurinol; hyperuricemia; resveratrol; uric acid; xanthine oxidase; URIC-ACID; IN-VITRO; OXIDOREDUCTASE; TOPIROXOSTAT; TYROSINASE;
D O I
10.1002/bab.2690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gout predominantly stems from hyperuricemia, precipitating the accumulation of urate crystals and consequent joint inflammation, swelling, and pain, thereby compromising the quality of life and presenting a formidable medical dilemma. Although conventional treatments like allopurinol and febuxostat target uric acid reduction via xanthine oxidase (XO) inhibition, they often entail adverse effects, prompting the exploration of safer alternatives. Resveratrol, a polyphenolic compound abundant in fruits and vegetables, has emerged as a potential XO inhibitor. However, its precise inhibitory mechanisms remain poorly understood. This study aims to comprehensively investigate resveratrol's XO inhibition through mechanistic insights, molecular docking simulations, animal model experiments, and biochemical analysis, contributing valuable insights to the development of novel therapeutics for hyperuricemia and gout.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators
    Sanchez, Concepcion
    Campeau, Anaamika
    Liu-Bryan, Ru
    Mikuls, Ted R.
    O'Dell, James R.
    Gonzalez, David J.
    Terkeltaub, Robert
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study
    Wang, Can
    Guo, Kai
    Dalbeth, Nicola
    Sun, Mingshu
    Lu, Jie
    Chen, Ying
    Zhang, Hui
    Wang, Xuefeng
    Ji, Xiaopeng
    Li, Xinde
    Sun, Wenyan
    Han, Lin
    Cui, Lingling
    Liu, Zhen
    Ji, Aichang
    He, Yuwei
    Terkeltaub, Robert
    Li, Changgui
    RHEUMATOLOGY, 2025,
  • [43] A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia
    Wang, Chenjing
    Yu, Qing
    Jiang, Xin
    Deng, Yujie
    Sun, Feifei
    Li, Xin
    Tao, Ye
    Lin, Pingping
    Ma, Yaping
    Zhu, Yuxian
    Li, Chengqian
    Cao, Yu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (02) : 239 - 249
  • [44] Placebo-Controlled Double-Blind Dose-Response Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia (Including Gout Patients) in Japan
    Naoyuki, Kamatani
    Shin, Fujimori
    Toshikazu, Hada
    Tatsuo, Hosoya
    Kenjiro, Kohri
    Toshitaka, Nakamura
    Takanori, Ueda
    Tetsuya, Yamamoto
    Hisashi, Yamanaka.
    Yuji, Matsuzawa
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) : S35 - S43
  • [45] Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets
    Balakumar, Pitchai
    Alqahtani, Ali
    Khan, Noohu Abdulla
    Mahadevan, Nanjaian
    Dhanaraj, Sokkalingam A.
    PHARMACOLOGICAL RESEARCH, 2020, 161
  • [46] Pyroptosis and Intervertebral Disc Degeneration: Mechanistic Insights and Therapeutic Implications
    Ge, Yuying
    Chen, Yuying
    Guo, Chijiao
    Luo, Huan
    Fu, Fangda
    Ji, Weifeng
    Wu, Chengliang
    Ruan, Hongfeng
    JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 5857 - 5871
  • [47] Combinatory effects of chlorhexidine and azithromycin: Implications for therapeutic potential and mechanistic insights
    Caglayan, Sinem Tuncer
    MICROBIAL PATHOGENESIS, 2025, 201
  • [48] Discovery of Natural Multitarget Xanthine Oxidase Inhibitors for Therapeutic Hyperuricemia Using Virtual Screening, Network Pharmacology and in vitro Experimental Verification
    Cao, Luxi
    Ma, Bei
    Yi, Bingxiang
    Liu, Yaru
    Sun, Jiaying
    CHEMISTRYSELECT, 2023, 8 (30):
  • [49] Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
    Tausche, Anne-Kathrin
    Alten, Rieke
    Dalbeth, Nicola
    Kopicko, Jeff
    Fung, Maple
    Adler, Scott
    Bhakta, Nihar
    Storgard, Chris
    Baumgartner, Scott
    Saag, Kenneth
    RHEUMATOLOGY, 2017, 56 (12) : 2170 - 2178
  • [50] Investigating neuroprotective roles of Bacopa monnieri extracts: Mechanistic insights and therapeutic implications
    Fatima, Urooj
    Roy, Sonam
    Ahmad, Shahnawaz
    Al-Keridis, Lamya Ahmed
    Alshammari, Nawaf
    Adnan, Mohd
    Islam, Asimul
    Hassan, Md. Imtaiyaz
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153